Katarzyna Tomela

Poznan, WP 61866, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Characteristics of Intestinal Barrier State and Immunoglobulin-Bound Fraction of Stool Microbiota in Advanced Melanoma Patients Undergoing Anti-PD-1 Therapy.

Characteristics of Intestinal Barrier State and Immunoglobulin-Bound Fraction of Stool Microbiota in Advanced Melanoma Patients Undergoing Anti-PD-1 Therapy.

Journal: International journal of molecular sciences

Published: June 12, 2025

Circulating Cell-Free Microbial DNA Signatures and Plasma Soluble CD14 Level Are Associated with Clinical Outcomes of Anti-PD-1 Therapy in Advanced Melanoma Patients.

Circulating Cell-Free Microbial DNA Signatures and Plasma Soluble CD14 Level Are Associated with Clinical Outcomes of Anti-PD-1 Therapy in Advanced Melanoma Patients.

Journal: International journal of molecular sciences

Published: October 24, 2024

Exploring correlations between gut mycobiome and lymphocytes in melanoma patients undergoing anti-PD-1 therapy.

Exploring correlations between gut mycobiome and lymphocytes in melanoma patients undergoing anti-PD-1 therapy.

Journal: Cancer immunology, immunotherapy : CII

Published: July 01, 2024

Gut Mycobiota Dysbiosis Is Associated with Melanoma and Response to Anti-PD-1 Therapy.

Gut Mycobiota Dysbiosis Is Associated with Melanoma and Response to Anti-PD-1 Therapy.

Journal: Cancer immunology research

Published: July 21, 2023

Host Factors Associated with Gut Mycobiome Structure.

Host Factors Associated with Gut Mycobiome Structure.

Journal: mSystems

Published: February 14, 2023

Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy.

Myeloid-Derived Suppressor Cells (MDSC) in Melanoma Patients Treated with Anti-PD-1 Immunotherapy.

Journal: Cells

Published: December 30, 2022

A Clinical Outcome of the Anti-PD-1 Therapy of Melanoma in Polish Patients Is Mediated by Population-Specific Gut Microbiome Composition.

A Clinical Outcome of the Anti-PD-1 Therapy of Melanoma in Polish Patients Is Mediated by Population-Specific Gut Microbiome Composition.

Journal: Cancers

Published: September 30, 2022

The standardisation of the approach to metagenomic human gut analysis: from sample collection to microbiome profiling.

The standardisation of the approach to metagenomic human gut analysis: from sample collection to microbiome profiling.

Journal: Scientific reports

Published: September 06, 2021

Influence of TGFBR2, TGFB3, DNMT1, and DNMT3A Knockdowns on CTGF, TGFBR2, and DNMT3A in Neonatal and Adult Human Dermal Fibroblasts Cell Lines.

Influence of TGFBR2, TGFB3, DNMT1, and DNMT3A Knockdowns on CTGF, TGFBR2, and DNMT3A in Neonatal and Adult Human Dermal Fibroblasts Cell Lines.

Journal: Current issues in molecular biology

Published: April 28, 2021

Secretory IgA in Intestinal Mucosal Secretions as an Adaptive Barrier against Microbial Cells.

Secretory IgA in Intestinal Mucosal Secretions as an Adaptive Barrier against Microbial Cells.

Journal: International journal of molecular sciences

Published: November 02, 2020

The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients.

The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients.

Journal: Life (Basel, Switzerland)

Published: August 17, 2020

Further evaluation of differential expression of keratoconus candidate genes in human corneas.

Further evaluation of differential expression of keratoconus candidate genes in human corneas.

Journal: PeerJ

Published: April 30, 2020

Showing 1-12 of 14

Last Updated: 09/26/2026